Eltrombopag

Eltrombopag Tablet

Eltrombopag is an oral medication used to increase platelet counts in patients with certain blood disorders. It helps reduce the risk of bleeding by stimulating the production of platelets in the bone marrow.

Description

• Generic Name: Eltrombopag

• Dosage Forms: Tablets (commonly available in 25mg & 50mg strengths)

• Therapeutic Class: Thrombopoietin Receptor Agonist

• Indications:

  • Chronic immune (idiopathic) thrombocytopenic purpura (ITP)

  • Severe aplastic anemia

  • Thrombocytopenia in patients with chronic hepatitis C (to allow treatment with interferon and ribavirin)

Mechanism of Action

• Eltrombopag is a thrombopoietin receptor agonist (TPO-RA).

• It binds to the transmembrane domain of the thrombopoietin receptor (c-Mpl) on megakaryocytes and progenitor cells.

• This stimulates platelet production, thereby reducing bleeding risks.

Dosage & Administration

• Dose depends on indication and patient’s condition.

• Typical starting dose: 25mg or 50mg once daily orally.

• Should be taken on an empty stomach (1 hour before or 2 hours after meals).

• Avoid taking with dairy products, antacids, or supplements containing aluminum, calcium, iron, magnesium, selenium, or zinc as they reduce absorption.

Side Effects

Common side effects may include:

• Headache

• Nausea

• Diarrhea

• Fatigue

• Muscle aches

• Increased liver enzymes

Serious but rare:

• Blood clots (thrombosis)

• Cataracts

• Hepatotoxicity (liver damage)

Precautions

• Regular monitoring of liver function tests (LFTs) and platelet counts is necessary.

• Not recommended during pregnancy unless clearly needed.

• Risk of thrombosis if platelet count rises too high.

Storage

• Store at room temperature (20°C – 25°C).

• Protect from moisture and light.

• Keep out of reach of children.

FAQs

Q1. What is Eltrombopag used for?
A: It is used to treat low platelet counts in ITP, aplastic anemia, and hepatitis C patients receiving therapy.

Q2. How long does it take to work?
A: Platelet counts may begin to rise within 1–2 weeks, but regular monitoring is required.

Q3. Can I take Eltrombopag with food?
A: Yes, but avoid dairy products or supplements containing calcium, iron, magnesium, aluminum, selenium, or zinc.

Q4. Is it a cure for ITP or aplastic anemia?
A: No, it is not a cure. It helps manage platelet counts and reduces the risk of bleeding.

TRUSTED Anti Cancer  MEDICINE PROVIDER – UNNATI PHARMAX

References:-

• European Medicines Agency (EMA) – Eltrombopag Accord (Generic Equivalent of Revolade)
  https://www.ema.europa.eu/en/medicines/human/EPAR/eltrombopag-accord European Medicines Agency (EMA)

• European Medicines Agency (EMA) – Eltrombopag Viatris (Another Authorized Generic)
  https://www.ema.europa.eu/en/medicines/human/EPAR/eltrombopag-viatris European Medicines Agency (EMA)

• European Medicines Agency (EMA) – Revolade (Original Brand)
  https://www.ema.europa.eu/en/medicines/human/EPAR/revolade European Medicines Agency (EMA)

• DailyMed – FDA-Approved Label for Eltrombopag Tablets
  https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e913cd11-f5fb-4ebe-81c7-0c5626b52cfd DailyMed+1

• National Cancer Institute (NCI), U.S. – Eltrombopag Drug Overview (Promacta)
  https://www.cancer.gov/about-cancer/treatment/drugs/eltrombopagolamine